This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Translational Prostate Cancer
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Education
Covid-19
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Pelvic Health & Reconstruction
Endourology
Testicular Cancer
Health Policy in Urological Diseases
Clinical Trials
From the Editor
Search Clinical Trials
Trials in Progress
DORA - PCCTC
IRONMAN - PCCTC
PROMISE - PCCTC
SPLASH Trial
Oral EPI-7386
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SUO 2022
ASCO GU 2023
EAU 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ESMO 2022
ESMO 2022
Prostate Cancer
Bladder Cancer
Testicular and Penile Cancer
Press Releases
Kidney Cancer
ESMO 2022 Bladder Cancer
Viewing 1-16 of 16 articles
ESMO 2022: Latest Imaging Advances in PET and Beyond Translated to Bladder and Kidney Cancers
ESMO 2022: Invited Discussant: The Phase III VESPER Trial & the Phase III CheckMate 274 Trial
ESMO 2022: Pure or Mixed Basal/squamous Tumours Present Decreased Outcomes After Neoadjuvant Chemotherapy in the GETUG-AFU V05 VESPER Trial
ESMO 2022: Study EV-103 Cohort K: Antitumor Activity of Enfortumab Vedotin Monotherapy or in Combination with Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
ESMO 2022: Tumor and Immune Features Associated with Disease-Free Survival with Adjuvant Nivolumab in the Phase 3 CheckMate 274 Trial
ESMO 2022: Disease-Free Survival and Distant Metastasis-Free Survival as Surrogates for Overall Survival in Adjuvant Treatment of Muscle-Invasive Bladder Cancer
ESMO 2022: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results from Patients with ≥12 Months of Treatment in JAVELIN Bladder 100
ESMO 2022: Prevalence of PD-L1 High Expression in Advanced Urothelial Carcinoma (aUC): Results from the PREVAIL Prospective Cohort Study
ESMO 2022: Phase 2 Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin in Patients (pts) With HER2-Expressing Urothelial Carcinoma (RC48G001, Trial in Progress)
ESMO 2022: A Discussion on Radiation Therapy Before Radical Cystectomy combined with Immunotherapy in Locally Advanced Urothelial Carcinoma, First Results from BladderPath, and BC2001 and BCON Randomised Trials
ESMO 2022: First Results from BladderPath: A Randomised Trial of MRI Versus Cystoscopic Staging for Newly Diagnosed Bladder Cancer
ESMO 2022: RACE IT - A Prospective, Single Arm, Multicenter, Phase II-Trial to Assess Safety and Efficacy of Preoperative RAdiation Therapy Before Radical CystEctomy Combined with ImmunoTherapy in Locally Advanced Urothelial Carcinoma of the Bladder
ESMO 2022: Hypoxic Bladder Cancers Have a Poorer Outcome Following Hypofractionated Vs Conventionally Fractionated Radiotherapy in the BC2001 and BCON Randomised Trials
ESMO 2022: PD-L1 Expression on Immune Cells by SP142 Co-Localizes with Dendritic Cells and Is Associated with Improved OS with Atezolizumab in Patients with Untreated Metastatic Urothelial Cancer
ESMO 2022: Biomarkers for Advanced Urothelial Carcinoma: Are We There Yet?
ESMO 2022: Genomic Biomarkers in Peripheral Blood From Patients Enrolled in the JAVELIN Bladder 100 Trial of Avelumab First-line Maintenance in Advanced Urothelial Carcinoma
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free